Editas Medicine (EDIT) Misses Q4 EPS by 9c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.84), $0.09 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $3.67 million versus the consensus estimate of $4.13 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold